The research status of the drug therapy for inflammatory bowel disease

BIAN Yingying; WANG Jie; LI An; KAI Guoyin; LU Yiming

doi:10.3969/j.issn.1006-0111.2017.03.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 35 Issue 3

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2017 > 35(3): 197-200,228

BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002

Citation:

BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002

The research status of the drug therapy for inflammatory bowel disease

doi: 10.3969/j.issn.1006-0111.2017.03.002

1.
College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China
2.
Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2016-09-20
Rev Recd Date: 2016-12-03

Abstract

Research on the inflammatory bowel disease(IBD) is a hot topic in the field of digestive system disease. IBD mainly consists of ulcerative colitis(UC) and Crohn's disease(CD). The pathogenesis of IBD has not been fully understood. So far, there is no specific medication for IBD. A number of novel medicines and preparations have emerged with the research progress on the pathogenesis of IBD. The research status on IBD drug therapy is briefly reviewed in this paper.
- inflammatory bowel disease,
- ulcerative colitis,
- Crohn's disease,
- drug therapy

References

[1]	Bernstein CN, Fried M, Krabshuis JH, et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学,2010,15(9):548-558.
[2]	郭小芹. IL-17/IL-17R通路在炎症性肠病中的免疫调节机制研究[D].北京:中国人民解放军军事医学科学院,2013.
[3]	Rammeart DC, Canling SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet,2007,369(9673):1627-1640.
[4]	Parkes M. The genetics universe of Crohn's disease and ulcerative colitis[J]. Dig Dis,2012,30(Suppl 1):78-81.
[5]	Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea[J]. Scand J Gastroenterol,2010,45(10):1178-1185.
[6]	牛润章,张兰兰,司依馨. 炎症性肠病的病因及诊治研究进展[J]. 实用医药杂志,2014,31(5):461-463.
[7]	欧阳钦. 炎症性肠病的病因和发病机制[J]. 实用医学杂志,2003,19(5):448-449.
[8]	Maesla S, Hsu LC, Lin H, et al. Nod-mutation in Crohn's disease potenliales NF-kappaB activity and IL-beta processing[J]. Science,2005,307(5710):734-738.
[9]	肖梅,吴正祥. 炎症性肠病的病因研究进展[J]. 安徽医药,2005,9(12):886-889.
[10]	Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeatic alternative[J]. Gastroenterology,1999,116(5):1246-1249.
[11]	欧阳钦. 炎症性肠病发病机制与治疗研究进展[J]. 中国处方药,2004,23(4):15-19.
[12]	Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induced and perpetuate experimental colitis in rats and mice[J]. Infect Immune,2001,69(4):2277-2285.
[13]	郭璟. 4-氨基水杨酸抗炎性肠病衍生物的合成研究[D]. 山西:山西医科大学,2004.
[14]	黄雪彪. 炎症性肠病的药物治疗[J]. 临床药物治疗杂志,2003,1(4):27-32.
[15]	Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology,1997,113(5):1465-1473.
[16]	Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis[J].Digestion,1984,29(4):204-208.
[17]	靳宝芬. 4-氨基水杨酸和5-氨基水杨酸抗炎作用及作用机制研究[D].山西:山西医科大学,2014.
[18]	蒋蔚茹. 炎症性肠病的认识与治疗进展[J]. 上海医药,2010,31(5):207-210.
[19]	刘凡. 炎症性肠病药物治疗现状与进展[J]. 沈阳医学院学报,2006,8(4):241-242.
[20]	Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2006,24(2):331-342.
[21]	Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol,2012,24(8):958-964.
[22]	Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma[J]. Gastroenterol,2000,118(6):1018.
[23]	Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopu-rine, mesalamine, or placebo: a 2-year trial[J]. Gastroenterology, 2004,127(3):723-729.
[24]	Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology,2006,130(3):935-939.
[25]	Feagan G, John M. Low-Dose Cyclosporine for the Treatment of Crohn's Disease[J]. Med, 1994,330(26):1846-1851.
[26]	Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis[J]. Clin Gastroenterol,2011,45(2):107-112.
[27]	崔静. 炎症性肠病发病机制和治疗方面某些进展[D].郑州:郑州大学,2004.
[28]	王俊珊,刘占举. 炎症性肠病的诊断和药物治疗相关指南解读[J]. 世界临床药物, 2005,36(12):809-813.
[29]	黄瑛,王玉环. 儿童炎症性肠病的药物治疗[J]. 世界临床药物,2009,30(8):459-464.
[30]	李世荣. 生物靶向药物在炎症性肠病中的应用现状[J]. 中国新药杂志,2010,19(19):1750-1757.
[31]	杨志红,邓彤斌,王梦明,等. 炎症性肠病的病因学和药物治疗研究进展[J]. 中国药师, 2013,16(6): 905-907.
[32]	高树娟,施瑞华. 炎症性肠病治疗的新进展[J]. 世界华人消化杂志,2012,36:3742-3747.
[33]	Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology,2011,100(1):75-79.
[34]	Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2010,132(1):1296-1309.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3471) PDF downloads(1202) Cited by()

Proportional views

The research status of the drug therapy for inflammatory bowel disease

1. College of Life and Environment Science, Shanghai Normal University, Shanghai 200234, China

2. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2016-09-20

Rev Recd Date: 2016-12-03

Key words:

Abstract: Research on the inflammatory bowel disease(IBD) is a hot topic in the field of digestive system disease. IBD mainly consists of ulcerative colitis(UC) and Crohn's disease(CD). The pathogenesis of IBD has not been fully understood. So far, there is no specific medication for IBD. A number of novel medicines and preparations have emerged with the research progress on the pathogenesis of IBD. The research status on IBD drug therapy is briefly reviewed in this paper.

HTML

Reference (34)

[1]	Bernstein CN, Fried M, Krabshuis JH, et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学,2010,15(9):548-558.
[2]	郭小芹. IL-17/IL-17R通路在炎症性肠病中的免疫调节机制研究[D].北京:中国人民解放军军事医学科学院,2013.
[3]	Rammeart DC, Canling SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet,2007,369(9673):1627-1640.
[4]	Parkes M. The genetics universe of Crohn's disease and ulcerative colitis[J]. Dig Dis,2012,30(Suppl 1):78-81.
[5]	Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea[J]. Scand J Gastroenterol,2010,45(10):1178-1185.
[6]	牛润章,张兰兰,司依馨. 炎症性肠病的病因及诊治研究进展[J]. 实用医药杂志,2014,31(5):461-463.
[7]	欧阳钦. 炎症性肠病的病因和发病机制[J]. 实用医学杂志,2003,19(5):448-449.
[8]	Maesla S, Hsu LC, Lin H, et al. Nod-mutation in Crohn's disease potenliales NF-kappaB activity and IL-beta processing[J]. Science,2005,307(5710):734-738.
[9]	肖梅,吴正祥. 炎症性肠病的病因研究进展[J]. 安徽医药,2005,9(12):886-889.
[10]	Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeatic alternative[J]. Gastroenterology,1999,116(5):1246-1249.
[11]	欧阳钦. 炎症性肠病发病机制与治疗研究进展[J]. 中国处方药,2004,23(4):15-19.
[12]	Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induced and perpetuate experimental colitis in rats and mice[J]. Infect Immune,2001,69(4):2277-2285.
[13]	郭璟. 4-氨基水杨酸抗炎性肠病衍生物的合成研究[D]. 山西:山西医科大学,2004.
[14]	黄雪彪. 炎症性肠病的药物治疗[J]. 临床药物治疗杂志,2003,1(4):27-32.
[15]	Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology,1997,113(5):1465-1473.
[16]	Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis[J].Digestion,1984,29(4):204-208.
[17]	靳宝芬. 4-氨基水杨酸和5-氨基水杨酸抗炎作用及作用机制研究[D].山西:山西医科大学,2014.
[18]	蒋蔚茹. 炎症性肠病的认识与治疗进展[J]. 上海医药,2010,31(5):207-210.
[19]	刘凡. 炎症性肠病药物治疗现状与进展[J]. 沈阳医学院学报,2006,8(4):241-242.
[20]	Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2006,24(2):331-342.
[21]	Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol,2012,24(8):958-964.
[22]	Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma[J]. Gastroenterol,2000,118(6):1018.
[23]	Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopu-rine, mesalamine, or placebo: a 2-year trial[J]. Gastroenterology, 2004,127(3):723-729.
[24]	Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology,2006,130(3):935-939.
[25]	Feagan G, John M. Low-Dose Cyclosporine for the Treatment of Crohn's Disease[J]. Med, 1994,330(26):1846-1851.
[26]	Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis[J]. Clin Gastroenterol,2011,45(2):107-112.
[27]	崔静. 炎症性肠病发病机制和治疗方面某些进展[D].郑州:郑州大学,2004.
[28]	王俊珊,刘占举. 炎症性肠病的诊断和药物治疗相关指南解读[J]. 世界临床药物, 2005,36(12):809-813.
[29]	黄瑛,王玉环. 儿童炎症性肠病的药物治疗[J]. 世界临床药物,2009,30(8):459-464.
[30]	李世荣. 生物靶向药物在炎症性肠病中的应用现状[J]. 中国新药杂志,2010,19(19):1750-1757.
[31]	杨志红,邓彤斌,王梦明,等. 炎症性肠病的病因学和药物治疗研究进展[J]. 中国药师, 2013,16(6): 905-907.
[32]	高树娟,施瑞华. 炎症性肠病治疗的新进展[J]. 世界华人消化杂志,2012,36:3742-3747.
[33]	Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology,2011,100(1):75-79.
[34]	Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2010,132(1):1296-1309.

Message Board

The research status of the drug therapy for inflammatory bowel disease

doi: 10.3969/j.issn.1006-0111.2017.03.002

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views